This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Data On AVEO Pharmaceuticals’ Tivozanib And AV-203 To Be Presented At AACR Annual Meeting 2012

AVEO Pharmaceuticals, Inc. (Nasdaq: AVEO) today announced that previously reported clinical data on tivozanib, AVEO’s lead product candidate designed to optimally block the VEGF pathway by inhibiting all three VEGF receptors, and preclinical data on AV-203, AVEO’s ErbB3 inhibitory antibody, will be presented during poster sessions at the American Association for Cancer Research (AACR) Annual Meeting 2012 being held March 31-April 4, 2012 in Chicago.

“We look forward to sharing these data among our peers in the oncology research community at this year’s AACR meeting as we prepare to initiate clinical development with AV-203, our internally-discovered ErbB3 inhibitory antibody, in the first half of this year,” said Jeno Gyuris, Ph.D., senior vice president and chief scientific officer at AVEO. “ErbB3 is widely expressed in many human cancers and its over-expression is often associated with poor prognosis in patients. An increasing body of evidence implicates the activation of ErbB3 in tumorigenesis and the development of resistance to anti-cancer agents. AV-203 has demonstrated high affinity binding to ErbB3 and the ability to potently inhibit both ligand-dependent and ligand-independent ErbB3 signaling in vitro and in vivo.”

The schedule for AVEO’s poster presentations is as follows:

Date & Time:
          Sunday, April 1, 2012 from 1:00 to 5:00 p.m. (CDT)

Poster Title:
The effect of food on the pharmacokinetics of tivozanib

Abstract:

#752

Location:
McCormick Place West, Hall F, Poster Section 28, #6
 

Date & Time:
Monday, April 2, 2012 from 1:00 to 5:00 p.m. (CDT)

Poster Title:

 
AV-203, a humanized ErbB3 inhibitory antibody inhibits ligand-dependent and ligand-independent ErbB3 signaling in vitro and in vivo

Abstract:
#2509

Location:
McCormick Place West, Hall F, Poster Section 19, #4
 

Date & Time:
Tuesday, April 3, 2012 from 8:00 a.m. to 12:00 p.m. (CDT)

Poster Title:
Pharmacokinetics and pharmacodynamics of AV-203, a humanized anti-ErbB3 antibody

Abstract:
#3787

Location:
McCormick Place West, Hall F, Poster Section 30, #22

Following the meeting, the AVEO posters will be available in the publications section of the AVEO website at investor.aveopharma.com.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

Chart of I:DJI
DOW 16,643.01 -11.76 -0.07%
S&P 500 1,988.87 +1.21 0.06%
NASDAQ 4,828.3250 +15.6170 0.32%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs